 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | simmiparib (SMOCL-9112) / Shanghai Acebright Pharma
Journal: Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer. (Pubmed Central) - Sep 23, 2021
Finally, we demonstrated that inhibition or depletion of GSK3β could enhance the in vivo sensitivity to simmiparib without toxicity. Our results provide a mechanistic understanding of the combination of PARP and GSK3 inhibition, and support the clinical development of this combination therapy for CRC patients.
- | Journal, BRCA Biomarker, PARP Biomarker: Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors. (Pubmed Central) - Oct 15, 2020
Finally, PARPi treatment or PARP1 depletion led to a marked increase in the mRNA and protein levels of COX-2 and BIRC3, indicating that PARP1 is a negative transcriptional regulator of these proteins. Together, our findings demonstrated that during the chronic treatment of cells with a PARPi, both BRCA2 intron 11 mutations and COX-2/BIRC3-mediated apoptotic resistance led to PARPi resistance in pancreatic Capan-1 cells.
- simmiparib (SMOCL-9112) / Shanghai Acebright Pharma
Enrollment open, Metastases: Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor (clinicaltrials.gov) - Jan 13, 2017
P1, N=50, Recruiting, Sponsor: Shanghai Acebright Pharmaceuticals Co., Ltd.
Together, our findings demonstrated that during the chronic treatment of cells with a PARPi, both BRCA2 intron 11 mutations and COX-2/BIRC3-mediated apoptotic resistance led to PARPi resistance in pancreatic Capan-1 cells. Not yet recruiting --> Recruiting
- simmiparib (SMOCL-9112) / Shanghai Acebright Pharma
New P1 trial, Metastases: Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor (clinicaltrials.gov) - Dec 15, 2016
P1, N=50, Not yet recruiting, Sponsor: Shanghai Acebright Pharmaceuticals Co., Ltd.